Sign in
Stories
Arcutis' Roflumilast Partnership in Japan
Share
Advancements in Cancer Treatment and Mar...
Biosimilar Partnership in U.S.
Breakthrough Briquilimab Data Unveiled
ANJESO Drug Insight and Market Forecast
Acne Relief: Stiftung Warentest's Top Pi...
Aldeyra Therapeutics R&D Day 2024
Overview
API
Arcutis partners with Sato Pharmaceutical in Japan to develop and market roflumilast, a non-steroidal treatment for skin diseases. The deal involves a $25 million upfront payment, potential milestone payments of up to $40 million, and royalties. Roflumilast targets conditions such as plaque psoriasis and atopic dermatitis, with Arcutis maintaining rights for the U.S. and other regions.
Ask a question
How could this collaboration influence the global landscape of dermatological treatments?
How might this partnership impact the availability of advanced skin treatments in Japan?
What competitive advantages does roflumilast offer compared to existing treatments in the market?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage
au.in